IMVT — Immunovant Cashflow Statement
0.000.00%
Last trade - 00:00- $2.68bn
- $1.96bn
Annual cashflow statement for Immunovant, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -107 | -157 | -211 | -259 | -414 |
| Depreciation | |||||
| Non-Cash Items | 19.5 | 35.4 | 33.4 | 42.2 | 49.6 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 4.57 | 15.1 | -10.9 | 2.63 | -12 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -83.3 | -106 | -188 | -214 | -376 |
| Capital Expenditures | -0.21 | -0.254 | -0.197 | -0.36 | -0.759 |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | -0.21 | -0.254 | -0.197 | -0.36 | -0.759 |
| Financing Cash Flow Items | -0.14 | 200 | -0.272 | -6.01 | -0.319 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 383 | 200 | 70.9 | 472 | 454 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 300 | 93.7 | -117 | 259 | 78.6 |